Clinical Importance of CD200 Expression in Colorectal Liver Metastasis

Background Approximately 30% of patients diagnosed with colorectal cancer (CRC) develop liver metastases. We evaluated the role of CD200, a potent immunosuppressive molecule, in colorectal liver metastases (CRLM). Methods We examined 110 patients who underwent curative liver resection for CRLM at our institution between 2000 and 2016. Based on the results of immunohistochemical analysis, the patients were divided into high-CD200 ( n = 47) and low-CD200 ( n = 63) expression groups. The relationships between CD200 expression and various clinicopathological outcomes were investigated. Results The overall survival (OS) of patients in the high-CD200 group was significantly worse than that in the low-CD200 group ( p = 0.009). Multivariate analysis showed that the independent prognostic factors in CRLM were maximum tumor size > 30 mm ( p = 0.002), preoperative carcinoembryonic antigen level > 20 ng/mL ( p